HDinHD: Open Source Science for the HD Research Community
The goal of HDinHD is to foster and support a collaborative community united in its drive to accelerate the development of therapeutics that will delay the onset and/or ameliorate the effects of Huntington’s disease. HDinHD seeks to achieve this through:
- Sharing HD-related primary scientific data
- Sharing analyses and computational models built from HD-related scientific data
- Providing browsing and data interrogation tools over both primary and analyzed data that facilitate data exploration and hypothesis generation
- Building a forum for HD researchers to highlight their data, tools, know-how and insight to the community
The HDinHD website – founded as a partnership between CHDI and the Coppola Lab at UCLA – is currently a joint development effort by CHDI, Bridlewood Consulting and Rancho BioSciences. As you will see when you Register for access, HDinHD highlights data and tools provided by the broader community. If you are interested in Contributing Data to HDinHD, suggest links to other HD-related scientific data or websites, or would otherwise like to provide Feedback to us, we encourage you to do so. HDinHD is for the community; please help us tailor and grow HDinHD in a direction that can make a difference to your research, and ultimately, to improve the lives of HD families.
Want to learn more about HDinHD?
| Watch a detailed video overview of HDinHD presented at the 16th Annual HD Therapeutics Conference (April 2021). The video outlines data resources and tools within HDinHD and provides a detailed demonstration of the new HD Explorer tool. |
Read the following publication introducing HDinHD: HDinHD: A Rich Data Portal for Huntington’s Disease Research, J Huntingtons Dis., 10, 405-412
Latest news and publications from around the HD Ecosystem
HDBuzz
- Evolving Needs, Evolving Care: Adapting Psychological Support Across Different Stages of Huntington’s Disease
- Sealing the gap: a case for slower, smarter DNA repair
- HDBuzz 2025 Annual Report: Here’s what you made possible
- Skyhawk reports encouraging 12-month results for oral Huntington’s disease drug SKY-0515
- May 2026: This Month in Huntington’s Disease Research
Literature
- Mitochondrial Dysfunction as a Driver of Neurodegeneration in Parkinson's and Huntington's Disease: Molecular Insights and Emerging Interventions
- Counseling patients in the predictive genetics clinic for Huntington's disease: A qualitative analysis of ethnographic observations
- 3-Nitropropionic Acid-Induced Huntington's Disease in Preclinical Models: Mechanisms, Peripheral Toxicities, Model Gaps, and Future Directions
- Neuroprotective Potential of Pinostrobin in a Rat Model of Huntington's Disease: Behavioural, Biochemical, and Molecular Docking Evidence
- Transposable element small RNAs and large RNAs in aging brains and implications in Huntington's and Parkinson's disease
News
- Kentucky Rep. Nemes urges prosecution over marijuana expansion; Beshear bites back
- [144] uniQure N.V. SEC Filing - QURE - Stock Titan
- Evotec Reports Results of the Annual General Meeting 2026 - Investing News Network
- Does PTC Therapeutics' (PTCT) SEPHIENCE Momentum and Board Shift Reframe Its ...
- Cork father hopeful of approval for life-changing drug for his son after meeting with Taoiseach




